Turning the hardest chemistry into first-in-class oral drugs
Kekulai develops oral small-molecule drugs against high-value targets where no drug-like molecules exist. Our Allchymie platform is purpose-built for the hardest chemistry, and every program makes the next one faster. Our first program went from no chemical matter to hit-to-lead in 12 weeks.
Investors
Partners
Our Team
Hannah Shen, PhD
Cofounder & CEO
- BridgeBio pre-20 employees. Started 15 drug programs. One now at NDA filing, one became GondolaBio ($300M spinoff).
- Grew Octant's pipeline from 1 to 5.
- Benchling employee #17.
Chaya Stern, PhD
Founding Head of Computational Chemistry
- Built platforms at DeepCure, supported drug programs at Odyssey.
- Architected Allchymie's multi-model framework.
Claudia Cremers
Founding Head of Discovery
- Drugged transcription factors at Flare Therapeutics from target ID to lead optimization.
- Expert chemical biologist with cross-functional expertise.
Ching-Yi Lin
Founding Head of Engineering
- Architected Kekulai's infrastructure and agentic operations.
- Built cloud-native systems at Salesforce and Microsoft with teams spanning four continents.
Contact us
hello@kekulai.com
